FDA-APPROVED PRODUCT THERAPY AREAS

FDA-approved Product

Therapy Areas

Sanofi’s focus in immunology includes moderate-to-severe atopic dermatitis (AD), moderate-to-severe asthma, inadequately controlled chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis (EoE), prurigo nodularis (PN), chronic spontaneuous urticaria (CSU), bullous pemphigoid (BP), moderate-to-severe rheumatoid arthritis (RA), and polymyalgia rheumatica (PMR).

Educational Resources

Asthma

Associated Clinical Guidelines and Recommendations
GINA | Global Initiative for Asthma | 2025
NHLBI | National Heart, Lung, and Blood Institute | 2020

Atopic Dermatitis

Chronic Rhinosinusitis with Nasal Polyposis
A review of the phase 4 EVEREST trial comparing the efficacy and safety of dupilumab to omalizumab in patients with severe chronic rhinosinusitis with nasal polyps with coexisting asthma.

Associated Clinical Guidelines and Recommendations
AAD | American Academy of Dermatology | 2023
AAAAI/ACAAI | American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology | 2012

Bullous Pemphigoid

BP US Approval Data Deck
A review of the phase 2/3 ADEPT trial of dupilumab in bullous pemphigoid, this deck discusses the efficacy and safety data informing the FDA approval of dupilumab in bullous pemphigoid.

EADV

Chronic Spontaneous Urticaria

CSU Data US Approval
A brief review of disease burden, clinical features, pathophysiology, and management for bullous pemphigoid, chronic spontaneous urticaria, atopic hand and foot dermatitis, and prurigo nodularis.

Chronic Obstructive Pulmonary Disease

PRO1 Dupilumab COPD NOTUS vs BOREAS Infographic
A top-line, side-by-side summary of key data from NOTUS and BOREAS, based on the NOTUS interim results press release and the BOREAS primary data publication evaluating dupilumab use in COPD.

PRO1 MVO COPD Value Proposition Deck
A presentation providing an overview of the COPD pathophysiology, disease burden, management, and economic burend, as well as the data from the dupilumab trials in COPD, NOTUS and BOREAS.

PRO1 BOREAS NOTUS Efficacy COPD EOS Infographic (US)
A high-level summary of posthoc data evaluating efficacy in exacerbation reduction and secondary endpoints of the NOTUS and BOREAS studies stratified by blood eosinophil counts at baseline.

GOLD 2026 2026 GOLD Report and Pocket Guide - Global Initiative for Chronic Obstructive Lung Disease - GOLD
ACG Guidelines 2025

Chronic Rhinosinusitis with Nasal Polyps

Associated Clinical Guidelines and Recommendations
AAAAI/ACAAI | American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology | 2023
Orlandi et al. | International Consensus Statement on Allergy and Rhinology: Rhinosinusitis (ICAR:RS) | 2021
Han et al. | US Multidisciplinary Consensus on a Stepwise Treatment Algorithm | 2021

Eosinophilic Esophagitis

Associated Clinical Guidelines and Recommendations
AGA/JTF | American Gastroenterological Association/Joint Task Force on Allergy-Immunology Practice Parameters | 2020
Official journal of the American College of Gastroenterology | ACG

Polymyalgia Rheumatica

Polymyalgia Rheumatica
A presentation providing an overview of polymyalgia rheumatica (PMR) and its management, including impact on quality of life, challenges associated with diagnosis, and the unmet needs resulting from currently available treatment options, in which glucocorticoids play a central role. The presentation also reviews the pathophysiology of PMR and the rationale for IL-6 inhibition as a potential future treatment.

Associated Clinical Guidelines and Recommendations
EULAR/ACR | European League Against Rheumatism/American College of Rheumatology | 2015
Dejaco et al. | International Treat-to-Target Recommendations | 2023

Prurigo Nodularis

Current Understanding and Disease Management of Prurigo Nodularis
A presentation providing a disease state overview of prurigo nodularis for a payer audience, including clinical presentation, epidemiology, burden, pathophysiology, and disease management.